We are live on ! Find out more
RNTX

Rein Therapeutics
RNTX

16 hedge funds and large institutions have $1.59M invested in Rein Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.5% more ownership

Funds ownership: 22.53% → 23.03% (+0.5%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

6% less funds holding

Funds holding: 17 → 16 (-1)

13% less capital invested

Capital invested by funds: $1.83M → $1.59M (-$241K)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
16
Holders Change
-1
Holders Change %
-5.88%
% of All Funds
0.25%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
1
Increased
3
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$34.2K
2
Renaissance Technologies
Renaissance Technologies
New York
+$5.26K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.49K
4
TRCT
Tower Research Capital (TRC)
New York
+$1.3K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$2.43K
2
William Blair & Company
William Blair & Company
Illinois
-$1.14K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$915
4
IGWM
ICA Group Wealth Management
Colorado
-$179
Name Holding Trade Value Shares
Change 		Change in
Stake
AIM
1
Alerce Investment Management
Illinois
$1.26M – – –
Geode Capital Management
2
Geode Capital Management
Massachusetts
$85.3K +$2.49K +1,467 +3%
Vanguard Group
3
Vanguard Group
Pennsylvania
$60.7K -$915 -539 -1%
William Blair & Company
4
William Blair & Company
Illinois
$44.1K -$1.14K -670 -2%
KL
5
KCK Ltd
Bermuda
$34K – – –
Susquehanna International Group
6
Susquehanna International Group
Pennsylvania
$30.4K +$34.2K +20,155 New
HighTower Advisors
7
HighTower Advisors
Illinois
$29K – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$29K +$5.26K +3,100 +20%
TRCT
9
Tower Research Capital (TRC)
New York
$6.85K +$1.3K +767 +20%
JWA
10
JFS Wealth Advisors
Pennsylvania
$2.42K – – –
Morgan Stanley
11
Morgan Stanley
New York
$1.9K – – –
US Bancorp
12
US Bancorp
Minnesota
$1.9K – – –
BlackRock
13
BlackRock
New York
$287 – – –
Bank of America
14
Bank of America
North Carolina
$190 – – –
Wells Fargo
15
Wells Fargo
California
$36 – – –
UBS Group
16
UBS Group
Switzerland
– -$2.43K -1,357 Closed
IGWM
17
ICA Group Wealth Management
Colorado
– -$179 -100 Closed

RNTX Hedge Fund Activity: Q3 2023 in Review

16 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q3 2023, worth a combined $1.59M — down 13% from $1.83M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of RNTX and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $34.2K. The largest seller was UBS Group, exiting entirely with an estimated $2.43K sold.

  • 16 institutional investors held Rein Therapeutics (RNTX) as of Q3 2023, down from 17 in Q2 2023.
  • Funds reported $1.59M of Rein Therapeutics stock for Q3 2023, down 13% quarter-over-quarter.
  • 1 fund opened new Rein Therapeutics positions in Q3 2023 and 2 closed out, a net change of -1 holder.
  • The largest Rein Therapeutics buyer in Q3 2023 was Susquehanna International Group, an estimated $34.2K added.
  • The largest Rein Therapeutics seller in Q3 2023 was UBS Group, an estimated $2.43K sold.

Based on aggregated 13F filings for Q3 2023.